GlassScriptPhysician profile
Shoaib Asgher
NPI 1689835431
$5,643.56
in general payments reported to CMS, 2019-2025
38 companies · $1,534 in 2025
The $1,534 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,094 · 2020: $329 · 2022: $640 · 2023: $955 · 2024: $1,092 · 2025: $1,534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,581.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $889.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $676.52 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $657.67 | 2022-2025 | Ubrelvy, Vraylar, Rinvoq |
| Amgen INC. | $484.88 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $452.67 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $332.70 | 2019-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Lilly USA, LLC | $327.63 | 2019-2025 | Mounjaro, Zepbound, Taltz |
| Exact Sciences Corporation | $236.67 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $207.86 | 2019-2025 | |
| Glaxosmithkline, LLC. | $146.78 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.76 | 2019-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $106.71 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.10 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $89.60 | 2019-2023 | Belsomra |
| Astellas Pharma US INC | $88.76 | 2019-2025 | Veozah |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shoaib Asgher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.